Single versus double autologous stem cell transplantation (ASCT). Results of multicenter randomized studies.
| . | N . | Median Follow-up (months) . | Results . |
|---|---|---|---|
| Abbreviations: ASCT, autologous stem cell transplantation; Bu, Busulfan; CR, complete remission; CTX, Cyclophosphamide; EFS, event-free survival; HD, high dose; IFM, Intergroupe Français du Myélome; MAG, Myeloma Auto Greffe; Mel, melphalan; OS, overall survival; PBSCT, peripheral blood stem cell transplantation; TBI, total body irradiation; VAD, vincristine, adriamycin, dexamethasone. | |||
| †In favor of the more intensive treatment arm. | |||
| ‡2 × 70 mg/m2 melphalan ± CTX-TBI/PBSCT. | |||
| §200 mg/m2 melphalan/PBSCT ± Bu-Mel/PBSCT. | |||
| ¶VAD + HD chemo + TBI/PBSCT vs 140 mg/m2 Mel/PBSCT + HD chemo + TBI/PBSCT. | |||
| IFM 9425 | 399 | 60 | Better EFS and OS† |
| Hovon26 ‡ | 255 | 33 | Higher CR rate† |
| Bologna27 § | 178 | 30 | No difference |
| MAG 9528 ¶ | 193 | 40 | No difference |
| . | N . | Median Follow-up (months) . | Results . |
|---|---|---|---|
| Abbreviations: ASCT, autologous stem cell transplantation; Bu, Busulfan; CR, complete remission; CTX, Cyclophosphamide; EFS, event-free survival; HD, high dose; IFM, Intergroupe Français du Myélome; MAG, Myeloma Auto Greffe; Mel, melphalan; OS, overall survival; PBSCT, peripheral blood stem cell transplantation; TBI, total body irradiation; VAD, vincristine, adriamycin, dexamethasone. | |||
| †In favor of the more intensive treatment arm. | |||
| ‡2 × 70 mg/m2 melphalan ± CTX-TBI/PBSCT. | |||
| §200 mg/m2 melphalan/PBSCT ± Bu-Mel/PBSCT. | |||
| ¶VAD + HD chemo + TBI/PBSCT vs 140 mg/m2 Mel/PBSCT + HD chemo + TBI/PBSCT. | |||
| IFM 9425 | 399 | 60 | Better EFS and OS† |
| Hovon26 ‡ | 255 | 33 | Higher CR rate† |
| Bologna27 § | 178 | 30 | No difference |
| MAG 9528 ¶ | 193 | 40 | No difference |